Literature DB >> 17595782

Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma.

Minoru Fukuda1, Yasushi Obase, Naoyuki Miyashita, Yoshihiro Kobashi, Keiji Mohri, Shiro Ueno, Makio Hayama, Katsuhiko Shimizu, Hironori Nishimura, Masao Nakata, Mikio Oka.   

Abstract

Thymic carcinoma is a rare neoplasm with a poor prognosis. We report the clinical course of a patient who received complete surgical resection after effective induction treatment. A 72-year-old woman with advanced thymic carcinoma (squamous cell carcinoma, stage IVb) was considered as nonresectable due to invasion of neighboring organs and mediastinal lymph node metastasis. Two cycles of chemotherapy, consisting of paclitaxel (180 mg/m2) plus cisplatin (80 mg/m2), combined with thoracic radiotherapy (total 54 Gy) were performed concurrently and complete radical resection could then be performed. She is currently alive and ambulatory and has remained disease-free for two years. This multimodal treatment may be a good treatment option for locally advanced thymic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595782

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Thymic carcinoma with combined resection of the hemisternum.

Authors:  Ryo Maeda; Noritaka Isowa; Hideyuki Onuma; Hiroshi Miura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

2.  Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study.

Authors:  Minoru Fukuda; Masafumi Yamaguchi; Takuya Yamazaki; Soichiro Funaki; Hiroshi Mukae; Junya Fukuoka; Kazuki Nabeshima; Hisashi Tateyama; Kazuto Ashizawa; Noriyuki Tomiyama; Masaki Hara; Takashi Seto; Meinoshin Okumura; Kenji Sugio
Journal:  Thorac Cancer       Date:  2022-07-22       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.